|
Synonyms: 3,4-dihydroxy-L-phenylalanine | Inbrija® (levodopa inhalation powder) | L-DOPA | Sinemet®
levodopa is an approved drug (FDA (1993), EMA (2003))
Compound class:
Metabolite
|
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| Levodopa is a dopamine precursor and has no intrinsic target interactions that convey its therapeutic actions. L-DOPA is transported across the blood-brain barrier by the L-type amino acid transporter 1 (LAT1; SLC7A5) and it is decarboxylated to dopamine by the endogenous enzyme dopa decarboxylase (DDC). |
| Natural/Endogenous Targets | ||
|
||
| Enzymes Catalysing Reactions with this Compound as a Substrate or Product | ||||||||||||
|
||||||||||||
| Transporters Moving this Compound Across a Lipid Membrane | ||||||||
|
||||||||
| Selectivity at GPCRs | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| Ligand mentioned in the following text fields |
| Catecholamine turnover overview |